Progress in biopharmaceutical development

被引:226
作者
Kesik-Brodacka, Malgorzata [1 ]
机构
[1] Inst Biotechnol & Antibiot, Dept Bioengn, Staroscinska 5, PL-02516 Warsaw, Poland
关键词
biobetter; biopharmaceutical; biosimilar; drug market; monoclonal antibodies; recombinant vaccines; TRANSGENIC PROTEIN-PRODUCTION; CYTOCHROME-P450; BM3; BISPECIFIC ANTIBODIES; TRASTUZUMAB EMTANSINE; NEXT-GENERATION; GENE-THERAPY; BIOSIMILARS; VACCINE; FUTURE; IDENTIFICATION;
D O I
10.1002/bab.1617
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Since its introduction in 1982, biopharmaceutical drugs have revolutionized the treatment of a broad spectrum of diseases and are increasingly used in nearly all branches of medicine. In recent years, the biopharmaceuticals market has developed much faster than the market for all drugs and is believed to have great potential for further dynamic growth because of the tremendous demand for these drugs. Biobetters, which contain altered active pharmaceutical ingredients with enhanced efficacy, will play an important role in the development of biopharmaceuticals. Another significant group of biopharmaceuticals are biosimilars. Their introduction in the European Union and, recently, the Unites States markets will reduce the costs of biopharmaceutical treatment. This review highlights recent progress in the field of biopharmaceutical development and issues concerning the registration of innovative biopharmaceuticals and biosimilars. The leading class of biopharmaceuticals, the current biopharmaceuticals market, and forecasts are also discussed.
引用
收藏
页码:306 / 322
页数:17
相关论文
共 131 条
[1]   Protein expression in Pichia pastoris: recent achievements and perspectives for heterologous protein production [J].
Ahmad, Mudassar ;
Hirz, Melanie ;
Pichler, Harald ;
Schwab, Helmut .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2014, 98 (12) :5301-5317
[2]   Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products [J].
Aiuti, Alessandro ;
Roncarolo, Maria Grazia ;
Naldini, Luigi .
EMBO MOLECULAR MEDICINE, 2017, 9 (06) :737-740
[3]  
[Anonymous], NEW INSIGHTS CELL CU
[4]  
[Anonymous], SCI CONS DEM BIOS RE
[5]  
[Anonymous], 2009, EMERGING HLTH CARE I
[6]  
Anour R, 2014, GABI J, V3, DOI 10.5639/gabij.2014.0304.039
[7]  
Baeshen MN, 2015, J MICROBIOL BIOTECHN, V25, P953
[8]   Applications of CRISPR technologies in research and beyond [J].
Barrangou, Rodolphe ;
Doudna, Jennifer A. .
NATURE BIOTECHNOLOGY, 2016, 34 (09) :933-941
[9]   Biosimilar, biobetter and next generation therapeutic antibodies [J].
Beck, Alain .
MABS, 2011, 3 (02) :107-110
[10]   The transgenic animal platform for biopharmaceutical production [J].
Bertolini, L. R. ;
Meade, H. ;
Lazzarotto, C. R. ;
Martins, L. T. ;
Tavares, K. C. ;
Bertolini, M. ;
Murray, J. D. .
TRANSGENIC RESEARCH, 2016, 25 (03) :329-343